Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6017603 | Experimental Neurology | 2014 | 12 Pages |
Abstract
The goal of the current manuscript was to replicate published data that show intrathecal infusions of Taxol® (paclitaxel), an anti-neoplastic microtubule stabilizing agent, reduce fibrogliotic scarring caused by a dorsal spinal hemisection (DHx) injury and increase functional recovery and growth of serotonergic axons after moderate spinal contusion injury. These experiments were completed as part of an NIH-NINDS contract entitled “Facilities of Research Excellence in Spinal Cord Injury (FORE-SCI) - Replication”. Here, data are presented that confirm the anti-scarring effects of Taxol after DHx injury; however, Taxol did not confer neuroprotection or promote serotonergic axon growth nor did it improve functional recovery in a model of moderate spinal contusion injury. Thus, only partial replication was achieved. Possible explanations for disparate results in our studies and published data are discussed.
Keywords
ECMDPIDHxdays post-injuryGFAPMCIDNIH5HTCSPG5-hydroxytryptamine (serotonin)Spinal cord injuryaxonRegenerationScar formationmicrocomputer imaging deviceBehaviorMicrotubuleBBBSerotoninNINDSsciNIH, National Institutes of HealthExtracellular matrixcontusionNational Institute of Neurological Disorders and StrokeReplicationHemisectionGlial fibrillary acidic proteinchondroitin sulfate proteoglycan
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Phillip G. Popovich, C. Amy Tovar, Stanley Lemeshow, Qin Yin, Lyn B. Jakeman,